EP2205228A2 - Pflaster mit hydrophilem pulver zur anwendung auf der haut - Google Patents
Pflaster mit hydrophilem pulver zur anwendung auf der hautInfo
- Publication number
- EP2205228A2 EP2205228A2 EP08839020A EP08839020A EP2205228A2 EP 2205228 A2 EP2205228 A2 EP 2205228A2 EP 08839020 A EP08839020 A EP 08839020A EP 08839020 A EP08839020 A EP 08839020A EP 2205228 A2 EP2205228 A2 EP 2205228A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- patch
- support
- hydrophilic powder
- powder
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000843 powder Substances 0.000 title claims abstract description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 230000036571 hydration Effects 0.000 claims description 6
- 238000006703 hydration reaction Methods 0.000 claims description 6
- 238000002255 vaccination Methods 0.000 claims description 6
- 229940088623 biologically active substance Drugs 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 238000000586 desensitisation Methods 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 20
- 239000000758 substrate Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 47
- 239000000853 adhesive Substances 0.000 description 19
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 230000035515 penetration Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003522 acrylic cement Substances 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920003075 Plasdone™ K-29/32 polymer Polymers 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- -1 immunogen Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention generally relates to devices for cutaneous application.
- the invention more particularly relates to products and methods for better skin fixation of devices such as patches or transdermal patches, intended to interact with the skin to moisturize or facilitate the absorption of cutaneous biologically active substances. It also relates to a method for the manufacture of such devices, as well as their uses, in the therapeutic, diagnostic and / or cosmetic field, for example.
- Cutaneous or percutaneous absorption is the transfer of a substance through the skin, typically from the outside to the blood. This absorption is generally defined as the sum of two phenomena: a penetration of the molecules into the layers of the skin, followed by resorption by the blood or lymphatic circulation from the papillary dermis and then the deep dermis.
- the penetration stage is physically a passive diffusion through each or some of the structures of the integument: the stratum corneum, the Malpighi epidermis, the dermis and the cutaneous appendages.
- Penetration in the broadest sense, does not necessarily imply a diffusion through all the structures of the integument, especially the deep ones, but it must preferably allow an exposure of the substance to the immune or circulatory system. Once absorbed, the substance is usually distributed in the body and then, after being metabolized, it is eliminated. The steps following percutaneous absorption are normally similar to those encountered for any other route of administration.
- the stratum corneum is the most effective barrier against the penetration of a substance: anatomically, the substance can penetrate in two ways: one through the intercellular spaces of the stratum corneum and through the horn cells themselves, other through the skin appendages. It has been mentioned that the passage of hydrophilic active principles into the stratum corneum is facilitated when these compounds are find in a humid atmosphere.
- the substance antigen, immunogen, adjuvant, etc.
- the substance is able to meet the immunologically competent cells and, in particular, the antigen-presenting cells such as the cells. of Langerhans whose role is essential in the immunological reaction of the body.
- patches are “adhesive”, that is to say that they are provided with a glue or an adhesive, typically acrylic type, ensuring the narrow maintenance of the patch on the skin.
- the document US2004 / 137004 relates to a transdermal patch that can comprise different formulations and an acrylic adhesive or in the form of a hydrogel.
- US2006 / 002949 relates to an unadjuvanted transcutaneous immunization method in which an antigen in powder form can be used.
- US2006 / 147509 relates to a device for transdermal delivery of an immunogen, comprising a saponin-sterol delivery system and an occlusive vehicle.
- WO00 / 43058 relates to a method of transdermal administration of active ingredient in the form of accelerated particles. The method uses either an injection with the PowderJect TM device or a patch held in place by an athletic band.
- WO02 / 07325 relates to a patch for transcutaneous immunization and the document
- WO2006 / 007366 relates to fusion proteins for transcutaneous immunization.
- the antigen may be used in the form of powder or liquid, alone or mixed with an adjuvant.
- an adhesive can be used to maintain the patch, it is either a resin or an aqueous adhesive.
- Patches are also known for moisturizing the skin.
- the patch does not necessarily contain active substance, but its application, in particular of occlusive format, creates a zone of hydration in contact with the skin.
- patches are mainly intended for the field of cosmetics.
- Patches of the prior art have disadvantages, particularly when the desired effect requires a strong adhesion of the patch, obtained by a conventional adhesive (acrylic for example).
- a conventional adhesive acrylic for example.
- the separation between the adhesive surface and the skin can indeed lead to irritation and a sensation of pain.
- the use of aqueous adhesives can lead to an alteration of the active ingredient on the patch and therefore a short shelf life.
- a compromise must therefore be found for the adhesive strength of the adhesive surface, in order to limit the sensation of pain during the withdrawal, while ensuring that the patch remains on the skin. This membership is relatively difficult to establish precisely because it can vary with the duration of storage of the patch before its application.
- the invention aims to solve one or more of these disadvantages.
- the invention indeed provides a hydrophilic adhesive patch for cutaneous application, characterized in that the adhesion of the patch to the skin is provided by a hydrophilic powder acquiring adhesion in the presence of water.
- This characteristic of the invention ensures better adhesion of the device during its application, ease of storage, no loss of adhesiveness as a function of the storage duration, stability of the active ingredient (maintained in dry form), and better penetration into the skin of any active substance due to the hydration (natural or artificial) necessary prior to the skin to the transformation of the hydrophilic powder into adhesive gel ..
- the advantages of this adhesive powder are: Compared to the use of a hydrogel: the patches using the hydrogel require that a large amount of hydrogel is deposited on the patch, generally over the entire surface of the patch, which makes its manipulation imprecise ; such a patch can not be worn on the skin as a conventional transdermal patch, under clothing, for example; in addition, the preservation of the hydrogel, wet by definition, in its packaging before installation, is limited (limited storage time); Finally, the use of hydrogel prevents the active ingredient, if any, from being presented in dry form, as some require to be preserved because the water contained in the hydrogel then moistens the skin. active ingredient.
- Some devices for cutaneous administration require, to obtain locally under the device hyperhydration in depth of the skin (for example to facilitate the passage of the asset) or better dissolution of the dry active ingredient disposed on the inner face (facing the skin) of the device, which is wetted the skin beforehand; the use, in this case, of a hydrophilic powder acquiring adhesiveness in the presence of water, allows the immediate adhesion of the device to the wet skin, which does not allow an acrylic or silicone type adhesive.
- a particular object of the invention thus relates to a patch for cutaneous application, comprising:
- a support having an application face on which the hydrophilic powder is disposed.
- the hydrophilic powder in dry form, thus acquires adhesion in the presence of water, thus allowing the patch to be maintained during its application to a skin which has been advantageously previously moistened.
- the hydrophilic powder may be disposed on all or part of the application face of the patch, over a sufficient area to allow adhesion.
- the hydrophilic powder is disposed on the periphery of the application face of the support.
- the hydrophilic powder forms pads distributed on the application side of the support.
- the hydrophilic powder is disposed over the entire surface of the application face of the support.
- the patch further comprises a biologically active substance.
- the substance is a powder mixed with the hydrophilic powder.
- the substance is disposed on an area (s) of the application side of the distinct support (s) of the hydrophilic powder.
- the hydrophilic powder comprises soluble polymer chains in water.
- the hydrophilic powder comprises cellulose gum, ethylcellulose, hydroethylcellulose, a copolymer of N-vinyl-2-pyrrolidone and of vinyl acetate, or a 1-vinyl-2 polymer. pyrrolidone.
- the patch further comprises a reservoir containing an aqueous solution placed in line with the hydrophilic powder.
- the patch comprises a waterproof packaging in which water vapor and the support and the hydrophilic powder are included.
- the support has a form of comma.
- the invention further relates to a method of manufacturing a patch, comprising the application of a hydrophilic powder acquiring adhesion in the presence of water on the application side of a support.
- the support may be of various shapes and types, and in particular of flat shape or not, and of polymer, plastic, metal, textile and / or biological material, solid or semi-solid, etc.
- the hydrophilic powder is applied to all or part of the application face. According to another variant, the hydrophilic powder is applied on the periphery of the application face or in the form of pads distributed on the application side of the support.
- the method further comprises a step of applying a biologically active substance on the face of the support.
- the substance is applied in powder form as a mixture with the hydrophilic powder.
- the substance and the hydrophilic powder are applied successively.
- the powder and / or the substance are maintained on the support by electrostatic type forces.
- Another subject of the invention relates to a method for the cutaneous application of a substance to the skin, comprising the application of a patch as defined above to the skin of a subject, the step of application being preceded or not by a step of pre-hydration of the skin.
- Another subject of the invention relates to a method for hydrating the skin of a subject, comprising the application of a patch as defined above to a skin area to be moisturized.
- Another subject of the invention relates to the use of a patch as defined above for the application of a substance to the skin, and / or for the delivery of a substance by epi- or trans- cutaneous to a subject, in particular a mammal, in particular a human being (for example a child or an adult).
- the patch may especially be used for the vaccination of subjects, for the desensitization of subjects, or for the delivery of any active substance, such as in particular biologically active and / or antigenic (poly) peptides, for example.
- the invention also relates to corresponding methods, comprising the application of a patch of the invention to the skin of a subject, the application step being preceded or not by a step of prehydrating the skin.
- the patch can be used for the delivery of any active substance.
- a particular object of the invention lies in a method of delivering an active substance to a subject, comprising (i) applying a patch according to the invention to the skin of a subject, the patch comprising said active substance, and (ii) maintaining the patch for a period of time allowing the transfer of the substance into the skin.
- the substance is typically of a polypeptide nature, such as a hormone, a cytokine, a growth factor, a trophic factor, etc.
- the substance contained in the patch may be formulated in any suitable vehicle or excipient, and may be in solid (powder), liquid, etc. form.
- the patch can be used for example for the vaccination of subjects against any pathogen.
- a particular object of the invention resides in a method of vaccinating a subject against a pathogen, comprising (i) the application of a patch according to the invention to the skin of a subject, the patch comprising a specific antigen of said pathogen, and (ii) maintaining the patch for a period of time allowing the transfer of the antigen into the skin.
- the pathogen may be of a varied nature (virus, bacterium, parasite, etc.) and the antigen is typically of a polypeptide or lipid nature.
- the patch can also be used for desensitizing subjects to allergens.
- a particular object of the invention lies in a method for desensitizing a subject to an allergen, comprising (i) applying a patch according to the invention to the skin of a subject, the patch comprising a specific antigen of said allergen, and (ii) maintaining the patch for a period of time allowing the transfer of the antigen into the skin.
- FIG 1 is a top view of the adhesive side of a patch according to the invention.
- FIG 2 is a side sectional view of the patch of Figure 1 placed in a package
- FIG. 3 is a view from above of the adhesive face of a patch variant
- FIG. 4 is a view from above of the adhesive face of another variant of patch
- FIG 5 is a side view of the face of a user on which the patch is applied.
- the invention proposes forming the adhesive for maintaining a patch by means of a hydrophilic powder that acquires adhesion in the presence of water.
- the invention is suitable for any type of patch, that is to say any device that can be applied to a skin area of a subject to bring it into contact with a substance or create a hydration zone.
- the device typically comprises a support which can be of various shapes and types, and in particular of flat shape or not, and of polymer material, plastic, metal, textile and / or biological material, solid or semi-solid, etc.
- patches described in documents EP 1 367 944 or FR2, 866,553 may be mentioned.
- patches typically include a polymeric material (eg, a plastic film) on the surface of which a powder can be attached via electrostatic forces.
- Another type of patch that can be used for the implementation of the invention is, for example, a patch described in application EP1356821, which mentions the successive use of an adhesive film, intended to remove part of the stratum corneum, and a patch for epicutaneous penetration of the vaccine.
- FIGS 1 and 2 illustrate a first embodiment of a patch 1 according to the invention, intended in this case for the dissemination of an active substance in the body of the user.
- the patch 1 comprises a support 4.
- the support 4 has an application face on which a hydrophilic powder 2 is disposed.
- a substance 3 is also advantageously arranged on the application face.
- the substance 3 is intended to penetrate the epidermis in a manner known per se.
- the hydrophilic powder 2 is present in dry form and acquires adhesion in the presence of water.
- the hydrophilic powder 2 then turns into a sticky gel on the skin, thus allowing the adhesion of the patch 1.
- the adhesion power of the patch 1 during its application is not reduced by a long storage period.
- the adhesion power in the presence of water is relatively reduced, which facilitates the removal of patch 1 without pain.
- the hydrophilic powder 2 is preferably a biocompatible and inert powder, it does not interact with the active ingredients of the substance 3 and does not create side reactions either.
- the hydrophilic powder 2 is advantageously a hydrocolloid or a hydrogel, that is to say that it comprises water-soluble polymer chains.
- the hydrophilic powder may especially comprise the following compounds: cellulose gum (in particular diffused under the commercial reference blanose), ethylcellulose (in particular diffused under the commercial reference ethocel), hydroethylcellulose (in particular diffused under the commercial reference (natrosol), a copolymer of N-vinyl-2-pyrrolidone and of vinyl acetate (especially diffused under the reference commercial Plasdone S-630), and / or a polymer of 1-vinyl-2-pyrrolidone (especially diffused under the commercial reference Plasdone K-29/32).
- Water intake can be achieved by various means: natural (perspiration, perspiration of the user during application) or artificial (external water supply, for example by means of a spray, glove, cotton, gel or moisturizer advantageously comprising more than 80% water).
- An artificial water supply can also be achieved by providing the patch 1 with a reservoir (not shown) and placed in line with the hydrophilic powder 2.
- the reservoir then includes an aqueous solution.
- the reservoir may be formed of a tear-off envelope so as to imbibe the hydrophilic powder 2.
- the hydrophilic powder 2 is integral with the periphery of the support 4.
- the hydrophilic powder 2 is disposed on the periphery of the application face of the support 4 and surrounds a surface covered with the substance 3.
- the periphery of the application face of the support 4 thus serves as a fastener on the user's skin, while the central part of the application face makes it possible to press the substance 3 against the skin of the user.
- the patch 1 advantageously comprises a sealed package 5 in which the support 4 is disposed.
- This conditioning 5 makes it possible to keep the hydrophilic powder 2 dry before the use of the patch 1.
- the packaging also protects the substance 3.
- the packaging 5 may have a zone of weakness intended to facilitate its tearing.
- FIG. 3 illustrates another embodiment of a patch 1 according to the invention.
- the patch 1 comprises pads 6 of hydrophilic powder distributed on the application side of the support 4.
- the pads 6 are distributed in a surface covered by the substance 3.
- the substance 3 is always close of a stud 6, which thus guarantees its good veneer against the skin of a user.
- FIG. 4 illustrates another embodiment of a patch 1 according to the invention.
- the application face of the support 4 is covered with a powder 7, comprising a mixture of the hydrophilic powder and the substance.
- a uniform adhesion of the powder 7 to the skin is ensured, which ensures a homogeneous application of the substance on the skin.
- the adhesion surface is thus optimized, which ensures a good maintenance of the patch 1 while avoiding a local concentration of efforts during the tearing of the patch 1.
- the Application side of the support 4 has electrostatic properties.
- hydrophilic powder 2 (and optionally the substance 3 in the form of powder) is kept in contact with the application face by electrostatic forces, as described in patent EP 1 367 944.
- electrostatic forces as described in patent EP 1 367 944.
- Other modes of application of the hydrophilic powder 2 can also be envisaged.
- FIGS. 1 to 4 are flat, other geometries may also be envisaged, in particular supports comprising a depression forming a chamber, tank patches, rigid or semi-rigid supports, planar or otherwise, and in different types of materials.
- the patches are approximately comma-shaped. As illustrated in FIG. 5, such a form of patch 1 is particularly suitable for an application on the face 8 of a user, between the cheekbone of the cheek and the nasal septum.
- the patch may comprise a peelable adhesive film overhanging the application side of the support, and thus the powder (2) and / or the substance 3.
- This peelable film allows the skin to be exfoliated to remove a part of the stratum corneum. Once the film is peeled, penetration into the body of the applied substance is improved.
- the patch 1 may especially be used for the vaccination of subjects, for the desensitization of subjects, or for the delivery of an active substance, such as in particular biologically active and / or antigenic (poly) peptides, for example.
- the patch can thus be used for the vaccination of subjects against any pathogen.
- a particular object of the invention lies in a method of vaccinating a subject against a pathogen, comprising (i) the application of a patch according to the invention to the skin of a subject, the patch comprising an antigen specific for said pathogen, (ii) maintaining the patch for a period of time allowing the transfer of the antigen into the skin. If necessary, an exfoliation step will precede the step of maintaining the patch.
- the pathogen may be of a varied nature (virus, bacterium, parasite, etc.) and the antigen is typically of a polypeptide or lipid nature.
- the patch can also be used for desensitizing subjects to allergens.
- the patch can also be used for the delivery of any active substance.
- the substance is typically of a polypeptide nature, such as a hormone, a cytokine, a growth factor, a trophic factor, etc.
- a patch according to the invention may also be covered only with the hydrophilic powder, in particular for moisturizing the skin of the user for cosmetic applications.
- An occlusive patch is for example obtained by arranging the hydrophilic powder on the periphery of the application face of the support.
- the hydrophilic powder may also form studs distributed on the application face of the support.
- the hydrophilic powder may also be disposed over the entire surface of the support.
- Such a patch may also include a sealed package in which the carrier and the hydrophilic powder are included.
- the process for manufacturing a patch according to the invention typically comprises a step of applying a hydrophilic powder to all or part of the application face of a support.
- the method also comprises the application of a biologically active substance to the application side of the patch support. Any powdering method known per se can be used.
- the hydrophilic powder may be secured to the periphery of the support, for example so as to surround a surface covered with an active substance.
- the hydrophilic powder can be applied to the support to form pads distributed on the application side of the support. These pads can be formed in a surface covered by the substance active.
- the areas of active substance and hydrophilic powder can be defined by powdering devices forming different patterns or using patterns.
- a mixture of hydrophilic powder and a powder including an active substance on the application side of the support.
- the application of a powder mixture is particularly suitable for a patch having a flat support.
- the hydrophilic powder and the active substance may also be applied to the application side of the support during successive distinct steps.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0757970A FR2921562B1 (fr) | 2007-10-01 | 2007-10-01 | Dispositif adhesif pour application cutanee |
| PCT/FR2008/051749 WO2009050403A2 (fr) | 2007-10-01 | 2008-09-30 | Patch pour application cutanee contenant une poudre hydrophile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2205228A2 true EP2205228A2 (de) | 2010-07-14 |
Family
ID=39493866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08839020A Withdrawn EP2205228A2 (de) | 2007-10-01 | 2008-09-30 | Pflaster mit hydrophilem pulver zur anwendung auf der haut |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100222753A1 (de) |
| EP (1) | EP2205228A2 (de) |
| JP (1) | JP2010540603A (de) |
| KR (1) | KR20100080778A (de) |
| CN (1) | CN101938997A (de) |
| AU (1) | AU2008313589A1 (de) |
| BR (1) | BRPI0817539A2 (de) |
| CA (1) | CA2700168A1 (de) |
| EA (1) | EA201070402A1 (de) |
| FR (1) | FR2921562B1 (de) |
| IL (1) | IL204587A0 (de) |
| MX (1) | MX2010003297A (de) |
| WO (1) | WO2009050403A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2924349B1 (fr) | 2007-12-03 | 2010-01-01 | Dbv Tech | Methode de desensibilitation aux allergenes |
| WO2010103116A2 (en) | 2009-03-13 | 2010-09-16 | Dbv Technologies | Method of treating eczema |
| CN107320722A (zh) | 2009-09-07 | 2017-11-07 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| WO2015059121A1 (en) | 2013-10-22 | 2015-04-30 | Dbv Technologies | Method of treating haemophilia by inducing tolerance to blood factors |
| USD1094728S1 (en) * | 2023-12-13 | 2025-09-23 | Shenzhen Kaiyan Medical Equipment Co., Ltd | Light therapy eye patch |
| USD1118944S1 (en) * | 2024-05-22 | 2026-03-17 | Ningbo Yimei Nikko-Seiki Manufacture Co., Ltd. | Eye patch |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3212495A (en) * | 1962-06-22 | 1965-10-19 | Hazleton Lab Inc | Sensitivity test patches |
| SE337223B (de) * | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
| US3837340A (en) * | 1971-10-20 | 1974-09-24 | Lilly Co Eli | Device for administering immunication against virus |
| US3894531A (en) * | 1974-04-12 | 1975-07-15 | Jr Milton A Saunders | Skin patch test device with peelable label |
| US4450844A (en) * | 1981-11-23 | 1984-05-29 | Hill Top Research, Inc. | Patch system for use on the skin |
| US4435180A (en) * | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
| SE8404895L (sv) * | 1984-10-01 | 1986-03-17 | Torkel Ingemar Fischer | Medel for en overkenslighetstest |
| US4743249A (en) * | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
| US4781705A (en) * | 1987-06-16 | 1988-11-01 | Zyton Inc. | Mineral applicator |
| US4788971A (en) * | 1987-07-13 | 1988-12-06 | Hill Top Research, Inc. | Patch system for use on the skin |
| US4821733A (en) * | 1987-08-18 | 1989-04-18 | Dermal Systems International | Transdermal detection system |
| US5438984A (en) * | 1988-09-08 | 1995-08-08 | Sudor Partners | Apparatus and method for the collection of analytes on a dermal patch |
| US5236455A (en) * | 1992-02-10 | 1993-08-17 | Wilk Peter J | Tympanic patch, applicator, and related method |
| JPH06145050A (ja) * | 1992-11-11 | 1994-05-24 | Sekisui Chem Co Ltd | 貼付剤の製造方法 |
| JPH0912448A (ja) * | 1995-04-28 | 1997-01-14 | Read Chem Kk | 薬物放出制御型経皮吸収製剤 |
| US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| EP1148902A1 (de) * | 1999-01-22 | 2001-10-31 | PowderJect Research Limited | Methode zur steigerung von nadelloser transdermaler medikamentenverabreichung in pulverform |
| FR2822049B1 (fr) * | 2001-03-13 | 2003-08-01 | Dbv Medica 1 | Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation |
| JP2004525921A (ja) * | 2001-03-19 | 2004-08-26 | イオマイ コーポレイシヨン | 経皮免疫用パッチ |
| US20040137004A1 (en) * | 2002-03-19 | 2004-07-15 | Glenn Gregory M | Patch for transcutaneous immunization |
| ATE449612T1 (de) * | 2002-10-02 | 2009-12-15 | Nordic Vaccine Technology As | Zusammensetzung zur impfung |
| US20060147509A1 (en) * | 2002-10-02 | 2006-07-06 | Kirkby Nikolai S | Composition for vaccination |
| US20090017056A1 (en) * | 2004-06-15 | 2009-01-15 | Iomai Corporation | Skin immunization using lt-sta fusion proteins |
-
2007
- 2007-10-01 FR FR0757970A patent/FR2921562B1/fr not_active Expired - Fee Related
-
2008
- 2008-09-30 MX MX2010003297A patent/MX2010003297A/es unknown
- 2008-09-30 JP JP2010527503A patent/JP2010540603A/ja active Pending
- 2008-09-30 EP EP08839020A patent/EP2205228A2/de not_active Withdrawn
- 2008-09-30 BR BRPI0817539 patent/BRPI0817539A2/pt not_active Application Discontinuation
- 2008-09-30 EA EA201070402A patent/EA201070402A1/ru unknown
- 2008-09-30 US US12/680,893 patent/US20100222753A1/en not_active Abandoned
- 2008-09-30 CA CA2700168A patent/CA2700168A1/fr not_active Abandoned
- 2008-09-30 WO PCT/FR2008/051749 patent/WO2009050403A2/fr not_active Ceased
- 2008-09-30 AU AU2008313589A patent/AU2008313589A1/en not_active Abandoned
- 2008-09-30 CN CN2008801098828A patent/CN101938997A/zh active Pending
- 2008-09-30 KR KR1020107007104A patent/KR20100080778A/ko not_active Withdrawn
-
2010
- 2010-03-18 IL IL204587A patent/IL204587A0/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2009050403A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201070402A1 (ru) | 2010-10-29 |
| US20100222753A1 (en) | 2010-09-02 |
| WO2009050403A2 (fr) | 2009-04-23 |
| FR2921562B1 (fr) | 2012-06-15 |
| BRPI0817539A2 (pt) | 2015-03-31 |
| CN101938997A (zh) | 2011-01-05 |
| WO2009050403A3 (fr) | 2009-06-25 |
| CA2700168A1 (fr) | 2009-04-23 |
| FR2921562A1 (fr) | 2009-04-03 |
| IL204587A0 (en) | 2010-11-30 |
| KR20100080778A (ko) | 2010-07-12 |
| MX2010003297A (es) | 2010-05-05 |
| JP2010540603A (ja) | 2010-12-24 |
| AU2008313589A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH661446A5 (fr) | Dispositif pour l'administration transdermique d'un medicament a un patient. | |
| EP0412869B1 (de) | Filmzusammensetzung zur Behandlung von Oberflächen und Verfahren zu ihrer Herstellung | |
| EP2117522B1 (de) | Pflaster zur anwendung auf der haut | |
| EP2205228A2 (de) | Pflaster mit hydrophilem pulver zur anwendung auf der haut | |
| CA2310138A1 (fr) | Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications | |
| EP2217222B1 (de) | Zusammensetzungen zur hautimmunisierung | |
| EP2011470A1 (de) | Anordnung, die ein Substrat aus Biozellulose umfasst und kosmetische Pulverzusammensetzung, die mit dem Substrat zusammengebracht werden muss | |
| ITMI20002216A1 (it) | Pellicola per la somministrazione dermica e transdermica di principi attivi | |
| EP1189587B1 (de) | Artikel für die kosmetik oder die dermatologie, der eine gefriergetrocknete hydrokolloidzusammensetzung enthält | |
| EP0213999B1 (de) | Von Bindegewebekulturen abstammendes kosmetisches Mittel | |
| EP1732525B1 (de) | Amorolfin-pflaster zur behandlung von onychomykose | |
| EP1865932B1 (de) | Aufladbares hautpflaster | |
| BE1028251B1 (fr) | Emplâtre médical à libération lente | |
| WO2010010240A2 (fr) | Timbre dermique pour l'application d'actifs secs | |
| EP1671613A1 (de) | Transungual system | |
| US20160008274A1 (en) | Treatment of nail disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20100319 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20160401 |